Airsupra Inhaler
Airsupra is a prescription rescue inhaler used as needed to treat asthma symptoms in adults. It combines two medications—albuterol, a fast-acting bronchodilator, and budesonide, an anti-inflammatory corticosteroid—into a single inhaler. Albuterol quickly relaxes airway muscles to ease breathing, while budesonide reduces inflammation in the lungs. Together, they help relieve symptoms like wheezing and shortness of breath and can reduce the risk of severe asthma attacks. Airsupra is not intended for daily maintenance therapy but is used during flare-ups or when symptoms arise.
- Combination inhaler containing albuterol and budesonide
- Pressurized metered-dose inhaler (MDI) with a built-in dose counter
- Not a maintenance inhaler and should not replace daily maintenance medications
- Should be primed before first use and re-primed if unused for more than 7 days
-
Airsupra Inhaler Medication Description
Airsupra represents a significant advancement in asthma rescue therapy by combining two well-established medications, albuterol and budesonide, into a single inhaler. Albuterol, a short-acting beta2-agonist (SABA), provides rapid relief by relaxing the smooth muscles in the airways, allowing them to open and ease breathing. Budesonide, an inhaled corticosteroid (ICS), works to reduce airway inflammation, which is a key contributor to asthma symptoms and exacerbations.
This dual-action approach addresses both the immediate symptoms and the underlying inflammation, making Airsupra more effective than traditional albuterol-only rescue inhalers. It is intended for use during asthma flare-ups or when symptoms occur, not as a daily maintenance therapy. Airsupra is typically administered as two inhalations per dose, with a maximum of six doses (12 inhalations) in a 24-hour period. It is important for patients to continue their regular maintenance medications and consult their healthcare provider if symptoms persist or worsen despite using Airsupra.
-
Airsupra Inhaler Side Effects
Common side effects of Airsupra include headache, cough, oral thrush (fungal infection in the mouth), and difficulty speaking. More serious side effects may involve paradoxical bronchospasm (worsening of breathing symptoms), fast or irregular heartbeat, high blood pressure, and allergic reactions such as hives or swelling of the face and throat. Long-term or excessive use may lead to adrenal suppression, reduced bone density, and increased risk of infections. Patients should rinse their mouth after each use to prevent oral thrush and monitor for symptoms like chest pain, vision changes, or severe dizziness. If any serious reactions occur, medical attention should be sought immediately. -
Consumer Information Use and Disclaimer
This information should not be used to decide whether or not to take this medicine or any other medicine. Only a healthcare provider has the knowledge and training to decide which medicines are right for you. TelyRx does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine’s uses from the patient education materials and is not intended to be comprehensive. This limited summary does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you may receive from your healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please review the entire patient education information you receive with the medication.
How TelyRx Works
1. You Choose
Request Your Prescription.
2. Doctors Review
Doctors Prescribe. Pharmacists Dispense.
3. We Deliver
Your Medication Arrives Quickly and Discreetly
Verified Customer Reviews
| Sex | Both |
|---|---|
| Pick and Pack | Yes |
| Order Flagging System | No |
| Set Cart Qty Limit | 4 |
| Robots Meta | INDEX, FOLLOW |

